FDA Grants Fast Track Designation To LPCN 1148 As Treatment For Sarcopenia

LPCN 1148 is targeted to be a 'First in Class' product candidate with a novel mechanism of action for management of cirrhosis.
11 hours ago
from: Contract Pharma

Fast track, Food and Drug Administration, Lipocine, NASDAQ:LPCN, Sarcopenia

More about this

- FDA fast tracks Lipocine's sarcopenia treatment
SALT LAKE CITY - Lipocine Inc. (NASDAQ: NASDAQ:LPCN), a biopharmaceutical company with a market capitalization of $26.7 million,...
from: Investing.com

- Lipocine Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. WASHINGTON, D.C. 20549. FORM 8-K. CURRENT REPORT. Pursuant to Section 13 or 15(d) of. The...
from: Quantisnow

- FDA fast tracks Lipocine’s oral androgen receptor agonist for sarcopenia in cirrhosis
The FDA granted fast track designation to Lipocine's LPCN 1148, an oral androgen receptor agonist containing testosterone dodecanoate, for...
from: Healio

- Lipocine's LPCN 1148 Secures FDA Fast Track Status for Groundbreaking Sarcopenia Treatment in Cirrhosis
Lipocine (NASDAQ: LPCN) has received Fast Track Designation from the FDA for LPCN 1148, targeting sarcopenia treatment in patients with...
from: Stock Titan

- FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis...
from: Morningstar